SCDS
MCID: SPR126
MIFTS: 39

Superior Semicircular Canal Dehiscence (SCDS)

Categories: Bone diseases, Ear diseases, Rare diseases

Aliases & Classifications for Superior Semicircular Canal Dehiscence

MalaCards integrated aliases for Superior Semicircular Canal Dehiscence:

Name: Superior Semicircular Canal Dehiscence 12 15
Superior Semicircular Canal Dehiscence Syndrome 12 53
Superior Canal Dehiscence Syndrome 53
Third Mobile Window Syndrome 12
Canal Dehiscence Syndrome 12
Superior Canal Dehiscence 12
Superior Canal Syndrome 12
Anemia, Sickle Cell 72
Scds 53

Classifications:



External Ids:

Disease Ontology 12 DOID:0080193
UMLS 72 C0002895

Summaries for Superior Semicircular Canal Dehiscence

NIH Rare Diseases : 53 Superior semicircular canal dehiscence syndrome is a rare balance disorder characterized by auditory and/or vestibular symptoms. These might include dizziness and vertigo triggered by heavy lifting, straining, coughing or loud sounds that change the middle ear or intracranial pressure, fullness in the ear, autophony (an echo or reverberation in the ear when speaking, chewing or swallowing), hearing loss, nystagmus, or oscillopsia (the apparent motion of objects that are stationary). This condition is caused by an opening (dehiscence) in the bone that overlays the superior (uppermost) semicircular canal within the inner ear. While many patients with superior semicircular canal dehiscence syndrome are able to tolerate their symptoms and reduce or avoid triggering stimuli, others can benefit from surgical repair of the dehiscence.

MalaCards based summary : Superior Semicircular Canal Dehiscence, also known as superior semicircular canal dehiscence syndrome, is related to sickle cell disease and schnyder corneal dystrophy, and has symptoms including angina pectoris, abdominal pain and edema. An important gene associated with Superior Semicircular Canal Dehiscence is COCH (Cochlin). The drugs Hydroxyurea and Deferasirox have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and endothelial.

Disease Ontology : 12 An inner ear disease characterized by dehiscence in the bone overlying the superior semicircular canal experience with symptoms of pressure or sound-induced vertigo, bone conduction hyperacusis, and pulsatile tinnitus.

Wikipedia : 75 Superior semicircular canal dehiscence syndrome is a set of hearing and balance symptoms, related to a... more...

Related Diseases for Superior Semicircular Canal Dehiscence

Diseases related to Superior Semicircular Canal Dehiscence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 135)
# Related Disease Score Top Affiliating Genes
1 sickle cell disease 12.4
2 schnyder corneal dystrophy 12.0
3 ehlers-danlos syndrome, spondylodysplastic type, 3 11.8
4 sickle cell anemia 11.8
5 cardiac conduction defect 11.6
6 hemoglobinopathy 11.5
7 qt interval, variation in 11.4
8 carnitine deficiency, systemic primary 11.3
9 spondylocostal dysostosis 3, autosomal recessive 11.2
10 subacute cerebellar degeneration 11.2
11 obsolete: secondary ciliary dyskinesia 11.2
12 semicircular canal dehiscence syndrome 11.1
13 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 11.0
14 pathologic nystagmus 10.8
15 otosclerosis 10.8
16 sensorineural hearing loss 10.7
17 hyperacusis 10.7
18 otitis media 10.6
19 cholesteatoma of middle ear 10.5
20 encephalocele 10.5
21 meniere disease 10.4
22 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.4
23 deafness, autosomal recessive 4, with enlarged vestibular aqueduct 10.4
24 deafness, autosomal dominant 9 10.4
25 ehlers-danlos syndrome 10.4
26 meningoencephalocele 10.4
27 perilymphatic fistula 10.4
28 hypertrophic cardiomyopathy 10.3
29 syncope 10.3
30 atrial standstill 1 10.3
31 acute chest syndrome 10.3
32 renal oncocytoma 10.3
33 hemosiderosis 10.3
34 congestive heart failure 10.3
35 rare hereditary hemochromatosis 10.3
36 osteoporosis 10.2
37 bone mineral density quantitative trait locus 8 10.2
38 bone mineral density quantitative trait locus 15 10.2
39 sleep apnea 10.2
40 fibrous dysplasia 10.2
41 meningocele 10.2
42 allergic hypersensitivity disease 10.2
43 patulous eustachian tube 10.2
44 acoustic neuroma 10.2
45 facial paralysis 10.2
46 labyrinthitis 10.2
47 neurilemmoma 10.2
48 intracranial hypertension 10.2
49 meningitis 10.2
50 48,xyyy 10.2

Comorbidity relations with Superior Semicircular Canal Dehiscence via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Heart Disease

Graphical network of the top 20 diseases related to Superior Semicircular Canal Dehiscence:



Diseases related to Superior Semicircular Canal Dehiscence

Symptoms & Phenotypes for Superior Semicircular Canal Dehiscence

UMLS symptoms related to Superior Semicircular Canal Dehiscence:


angina pectoris, abdominal pain, edema, chest pain

Drugs & Therapeutics for Superior Semicircular Canal Dehiscence

Drugs for Superior Semicircular Canal Dehiscence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 377)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydroxyurea Approved Phase 4 127-07-1 3657
2
Deferasirox Approved, Investigational Phase 4 201530-41-8 5493381
3
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
4
Acetaminophen Approved Phase 4 103-90-2 1983
5
Sulfadoxine Approved, Investigational Phase 4 2447-57-6 17134
6
Pyrimethamine Approved, Investigational, Vet_approved Phase 4 58-14-0 4993
7
Amodiaquine Approved, Investigational Phase 4 86-42-0 2165
8
Proguanil Approved Phase 4 500-92-5 4923
9
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
10
Desogestrel Approved Phase 4 54024-22-5 40973
11
Etonogestrel Approved, Investigational Phase 4 54048-10-1 6917715 40976
12
Deferiprone Approved Phase 4 30652-11-0 2972
13
Propranolol Approved, Investigational Phase 4 525-66-6 4946
14
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
15
Levetiracetam Approved, Investigational Phase 4 102767-28-2 441341
16
Memantine Approved, Investigational Phase 4 19982-08-2 4054
17
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
18
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
19
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
20
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
21
Amitriptyline Approved Phase 4 50-48-6 2160
22
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
23
Sumatriptan Approved, Investigational Phase 4 103628-46-2 5358
24
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
25
Rotigotine Approved Phase 4 99755-59-6, 92206-54-7 57537
26
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
27
Topiramate Approved Phase 4 97240-79-4 5284627
28
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
29
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
30
Rizatriptan Approved Phase 4 144034-80-0, 145202-66-0 5078
31
Donepezil Approved Phase 4 120014-06-4 3152
32
Zolmitriptan Approved, Investigational Phase 4 139264-17-8 441240 60857
33
Pramipexole Approved, Investigational Phase 4 104632-26-0 59868 119570
34
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
35
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
36
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
37
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
38
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
39
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
40
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 6433735 5283731
41
Dihydroartemisinin Experimental, Investigational Phase 4 71939-50-9 6918483
42
Piperaquine Experimental, Investigational Phase 4 4085-31-8 5079497
43 Tocotrienol Investigational Phase 4 6829-55-6
44
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
45 Nucleic Acid Synthesis Inhibitors Phase 4
46 Liver Extracts Phase 4
47 Chelating Agents Phase 4
48 Antipyretics Phase 4
49 Folic Acid Antagonists Phase 4
50 Renal Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 676)
# Name Status NCT ID Phase Drugs
1 Effect of Mobile-Directly Observed Therapy (DOT) on Adherence to Hydroxyurea Treatment in Adult HbSS Patients at Muhimbili National Hospital (MNH) in Tanzania: a Pilot Study Unknown status NCT02844673 Phase 4 Hydroxyurea
2 Evaluation of the Impact of Renal Function on the Pharmacokinetics of Hydroxyurea (SIKLOS ®) in Normal-renal Function, Hyperfiltrating and Renal Failure Sickle Cell Disease Patients (DARH) Completed NCT02522104 Phase 4 Siklos
3 Intranasal Fentanyl for Initial Treatment of a Vaso-occlusive Crisis: A Randomized, Double Blind Placebo Controlled Trial Completed NCT01482091 Phase 4 Fentanyl Citrate;Normal Saline
4 Rejuvesol® Washed RBC in Sickle Cell Patients Requiring Frequent Transfusions Completed NCT02731157 Phase 4 Rejuvesol
5 Pilot Pharmacokinetic Study In Patients With Inadequate Response To Deferasirox (Exjade) Completed NCT00749515 Phase 4 Deferoxamine;Deferasirox
6 Intranasal Fentanyl Versus Intravenous Morphine in the Emergency Department Treatment of Severe Painful Sickle Cell Crises in Children Completed NCT03682211 Phase 4 Fentanyl Citrate;Morphine sulphate
7 Future of Spermatogenesis in Men With Sickle Cell Disease Medically Treated. Completed NCT01609192 Phase 4 Hydrea® (hydroxyurea )
8 Comparing Acute Pain Management Protocols for Patients With Sickle Cell Disease Completed NCT02222246 Phase 4 Hydromorphone (Standardized, weight-based dosing);Morphine Sulfate (Standardized, weight-based dosing);Hydromorphone (Patient Specific dosing);Morphine Sulfate (Patient Specific dosing)
9 Does IV Acetaminophen Reduce Opioid Requirement in Pediatric Emergency Department Patients With Acute Sickle Cell Crises? Recruiting NCT03541980 Phase 4 Acetaminophen;Normal saline
10 The Efficacy and Safety of Ferriprox® for the Treatment of Transfusional Iron Overload in Patients With Sickle Cell Disease or Other Anemias Recruiting NCT02041299 Phase 4 Deferiprone;Deferoxamine
11 Enhancing Preventive Therapy of Malaria In Children With Sickle Cell Anemia in East Africa (EPiTOMISE) Recruiting NCT03178643 Phase 4 Proguanil Oral Tablet;Sulfadoxine/Pyrimethanine-Amodiaquine (SP-AQ);Dihydroartemisinin-Piperaquine (DP)
12 Endothelial Monocyte-activating Polypeptide-II as an Endothelial Dysfunction Marker and Its Relation to the Oxidative Stress in Egyptian Sickle Patients Active, not recruiting NCT03903133 Phase 4 Vitamin E
13 Risk Stratification for Clinical Severity of Sickle Cell Disease in Nigeria and Assessment of Efficacy and Safety During Treatment With Hydroxyurea Active, not recruiting NCT02149537 Phase 4 hydroxyurea
14 Use of Etonogestrel-releasing Contraceptive Implant in Women With Sickle Cell Disease Active, not recruiting NCT02594462 Phase 4 etonogestrel-releasing implant contraceptive
15 Long-term Safety and Efficacy Study of Ferriprox® for the Treatment of Transfusional Iron Overload in Patients With Sickle Cell Disease or Other Anemias Enrolling by invitation NCT02443545 Phase 4 Deferiprone
16 A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 (Stoss Therapy) in Pediatric Patients Undergoing HSCT to Prevent Vitamin D Deficiency and Insufficiency During Transplant Enrolling by invitation NCT03176849 Phase 4
17 Quality Improvement and Practice Based Research in Neurology Using the Electronic Medical Record Enrolling by invitation NCT02670161 Phase 4 Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)
18 Early Low-dose Ketamine Infusion Versus Usual Care for Sickle Cell Pain Crisis: a Randomized, Prospective Study. Not yet recruiting NCT04005209 Phase 4 Ketamine
19 An Open, Multicenter Clinical Trial to Investigate the Immunogenicity and Safety of the Pneumococcal 7-Valent Conjugate Vaccine (PREVENAR) in Sickle Cell Disease Infants. Terminated NCT00368186 Phase 4
20 A Pilot Study on the Effects of Intravenous Ketamine on Acute Pain Crisis in Patients With Sickle Cell Disease Terminated NCT00252122 Phase 4 Ketamine
21 An Evaluation of the Effectiveness of Ibuprofen and Opioid (Morphine or Diamorphine) for Acute Pain in Sickle Cell Disease: a Double-blind, Placebo-controlled Randomised Trial Terminated NCT00880373 Phase 4 Ibuprofen;Placebo;Diamorphine or Morphine
22 Ketorolac Versus Ibuprofen for the Painful Crisis of Sickle Cell Disease - Southwestern Comprehensive Sickle Cell Center Terminated NCT00115336 Phase 4 Intravenous Ketorolac;Ibuprofen
23 Endothelial Function in Patients With Sickle Cell Anemia Before and After Sildenafil Withdrawn NCT00937144 Phase 4 Viagra (Sildenafil);placebo
24 Non-Invasive Assessment of Opioid Analgesia in Children With Sickle Cell Disease Withdrawn NCT00513864 Phase 4 Dextromethorphan;Codeine;Morphine
25 Transfusion Alternatives Pre-Operatively in Sickle Cell Disease Unknown status NCT00512577 Phase 3
26 Omega 3 Fatty Acid Therapy for Prevention of Vaso-occlusive Crisis and Manifestations in Omani Patients With Sickle Cell Disease Unknown status NCT02525107 Phase 3
27 Ketamine as an Adjuvant Therapy for Acute Vaso Occlusive Crisis in Pediatric Patients With Sickle Cell Disease, a Pilot Study Unknown status NCT02801292 Phase 3 Ketamine
28 A Prospective Randomized Comparative Study of Efficacy and Safety of Combined Deferiprone (DFP) and Deferasirox Versus DFP and Desferrioxamine (DFO) Therapy in Diseases With Severe Iron Overload Unknown status NCT01511848 Phase 2, Phase 3 DFP (ferriprox) and deferasirox (ICL 670);DFP, DFO
29 Development of a Ready-to-use Nutraceutical Food for Patients With Sickle Cell Disease (SCD): Testing of Vascular Support Components Unknown status NCT01718054 Phase 2, Phase 3 Chloroquine
30 A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIVIPANSEL (GMI-1070) IN THE TREATMENT OF VASO-OCCLUSIVE CRISIS IN HOSPITALIZED SUBJECTS WITH SICKLE CELL DISEASE Completed NCT02187003 Phase 3 Rivipansel
31 MAST - Magnesium for Sickle Cell Acute Crisis in Children Completed NCT00313963 Phase 3 Magnesium Sulfate;Normal Saline
32 Evaluation of Repeat Administration of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC-E): An Open-Label Safety Extension Trial Assessing Repeat Administration of MST-188 (Purified Poloxamer 188) Injection in Subjects With Sickle Cell Disease Experiencing Vaso Occlusive Crisis Completed NCT02449616 Phase 3 MST-188
33 Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC): A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of MST-188 (Purified Poloxamer 188) Injection in Subjects With Sickle Cell Disease Experiencing Vaso Occlusive Crisis Completed NCT01737814 Phase 3 Saline;MST-188
34 A Study to Provide Expanded Access of (Exjade®) Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload From Blood Transfusions Who Cannot Adequately be Treated With Other Locally Approved Iron Chelators Completed NCT00235391 Phase 3 Deferasirox
35 Phase III Randomized Study of Poloxamer 188 for Vaso-Occlusive Crisis of Sickle Cell Disease Completed NCT00004408 Phase 3 poloxamer 188
36 A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine in Children With Sickle Cell Disease Previously Immunized With 23vPS Vaccine Completed NCT00918580 Phase 3
37 Stroke Prevention in Sickle Cell Anemia (STOP 1) Completed NCT00000592 Phase 3
38 Penicillin Prophylaxis in Sickle Cell Disease (PROPS) Completed NCT00000585 Phase 3 penicillin
39 Ameliorating Attention Problems in Children With SCD Completed NCT01411280 Phase 3 methylphenidate
40 A Randomized, Controlled, Double-blind Clinical Trial of L-arginine as Adjuvant Therapy for Sickle Cell Disease Completed NCT01142219 Phase 3 L-arginine;Placebo
41 N-Acetylcysteine in Patients With Sickle Cell Disease - Reducing the Incidence of Daily Life Pain Completed NCT01849016 Phase 3 N-Acetylcysteine;Placebo
42 A PHASE III, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY OF L GLUTAMINE THERAPY FOR SICKLE CELL ANEMIA AND SICKLE ß0-THALASSEMIA Completed NCT01179217 Phase 3 L-glutamine;Placebo
43 Bicentric Study of the Effect of Inhaled Nitric Oxide Compared to Placebo in Acute Chest Syndrome of Adult Sickle Cell Patients Completed NCT00748423 Phase 2, Phase 3 Nitric Oxide;Placebo
44 Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis Completed NCT01197417 Phase 2, Phase 3 Intravenous Magnesium Sulfate;Normal Saline Placebo
45 Presumptive Treatment With Sulfadoxine- Pyrimethamine Versus Weekly Chloroquine for Malaria Prophylaxis in Children With Sickle Cell Anemia Completed NCT00399074 Phase 3 sulfadoxine pyrimethamine
46 Choosing Opioid Management for Pain and Analyzing ACS Rates Equally Completed NCT01380197 Phase 3 Morphine;Nubain
47 Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG) Completed NCT00006400 Phase 3 Hydroxyurea;Placebo
48 Stroke Prevention in Sickle Cell Anemia (STOP 2) Completed NCT00006182 Phase 3
49 Evaluation of the Lung Capillary Blood Volume in Children With Sickle Cell Disease Completed NCT00560261 Phase 3
50 Multicenter Study of Hydroxyurea in Patients With Sickle Cell Anemia (MSH) Completed NCT00000586 Phase 3 hydroxyurea

Search NIH Clinical Center for Superior Semicircular Canal Dehiscence

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Sodium phenylbutyrate

Genetic Tests for Superior Semicircular Canal Dehiscence

Anatomical Context for Superior Semicircular Canal Dehiscence

MalaCards organs/tissues related to Superior Semicircular Canal Dehiscence:

41
Bone, Bone Marrow, Endothelial, T Cells, Kidney, Testes, Liver

Publications for Superior Semicircular Canal Dehiscence

Articles related to Superior Semicircular Canal Dehiscence:

(show top 50) (show all 310)
# Title Authors PMID Year
1
Why and when to refer patients for vestibular evoked myogenic potentials: A critical review. 38
31299589 2019
2
Outcomes of transmastoid resurfacing for superior canal dehiscence using a cartilage overlay technique. 38
30632156 2019
3
CT evaluation of normal bone thickness overlying the superior semicircular canal. 38
31103254 2019
4
Surgical treatments for a case of superior canal dehiscence syndrome associated with patulous Eustachian tube. 38
30287116 2019
5
Superior semicircular canal dehiscence postoperative outcomes: A case series of 156 repairs. 38
31383473 2019
6
Systematic Review of Round Window Operations for the Treatment of Superior Semicircular Canal Dehiscence. 38
31418721 2019
7
Can Wideband Tympanometry Be Used as a Screening Test for Superior Semicircular Canal Dehiscence? 38
30458602 2019
8
Failure to close the gap: Concomitant superior canal dehiscence in otosclerosis patients. 38
31271445 2019
9
Comparison of Transmastoid and Middle Fossa Approaches for Superior Canal Dehiscence Repair: A Multi-institutional Study. 38
30832543 2019
10
Posterior semicircular canal dehiscence: a diagnostic and surgical conundrum. 38
31270089 2019
11
Middle fossa approach for spontaneous cerebrospinal fluid fistula and encephaloceles. 38
31335556 2019
12
Age and gender considerations on the symptomology in patients with superior semicircular canal dehiscence: A systematic review and case illustration. 38
31078378 2019
13
The variation of superior semicircular canal bone thickness in relation to age and gender. 38
31035843 2019
14
Sealing of superior semicircular canal dehiscence is associated with improved balance outcomes postoperatively versus plugging of the canal in middle fossa craniotomy repairs: a case series. 38
31252395 2019
15
Repair of Temporal Bone Defects via the Middle Cranial Fossa Approach: Treatment of 2 Pathologies With 1 Operation. 38
29788439 2019
16
A Comparison of Two Recording Montages for Ocular Vestibular Evoked Myogenic Potentials in Patients with Superior Canal Dehiscence Syndrome. 38
30461389 2019
17
Prevalence of Superior Semicircular Canal Dehiscence on High-Resolution CT Imaging in Patients without Vestibular or Auditory Abnormalities. 38
30819770 2019
18
Skull vibration induced nystagmus in patients with superior semicircular canal dehiscence. 38
31029487 2019
19
The Prevalence of Superior Semicircular Canal Dehiscence in Patients With Mastoid Encephalocele or Cerebrospinal Fluid Otorrhea. 38
30870362 2019
20
Clinical Assessment of Patients with Bilateral Superior Semicircular Canal Dehiscence. 38
30928582 2019
21
Flat Panel Computed Tomography in the Diagnosis of Superior Semicircular Canal Dehiscence Syndrome. 38
30570605 2019
22
Bilateral Superior Semicircular Canal Dehiscence Associated with Ehlers-Danlos Syndrome: A Report of 2 Cases. 38
30385359 2019
23
Clinical and Physiologic Predictors and Postoperative Outcomes of Near Dehiscence Syndrome. 38
30570606 2019
24
Functional and Objective Audiovestibular Evaluation of Children With Apparent Semicircular Canal Dehiscence-A Case Series in a Pediatric Vestibular Center. 38
31001191 2019
25
Otolith Function Testing. 38
30947185 2019
26
Vestibular evoked myogenic potentials in practice: Methods, pitfalls and clinical applications. 38
30949613 2019
27
A Cohort Study of Hearing Outcomes Between Middle Fossa Craniotomy and Transmastoid Approach for Surgical Repair of Superior Semicircular Canal Dehiscence Syndrome. 38
30444849 2018
28
Superior semicircular canal dehiscence with concomitant otosclerosis-A literature review and case discussion. 38
30564330 2018
29
[Optimization of delivering minimum Gd-DTPA at the posterior upper point on tympanic medial wall and hT2W-3D-FLAIR sequence for detecting endolymphatic hydrops]. 38
30585006 2018
30
The Gopen-Yang Superior Semicircular Canal Dehiscence Questionnaire: development and validation of a clinical questionnaire to assess subjective symptoms in patients undergoing surgical repair of superior semicircular canal dehiscence. 38
30674366 2018
31
Postoperative MR imaging features after superior semicircular canal plugging in Minor syndrome. 38
30220585 2018
32
Anterior Canal benign paroxysmal positional Vertigo following surgical Management of superior canal dehiscence. 38
30224218 2018
33
Semicircular Canal Dehiscence Syndrome and Vestibular Dysfunction Disqualify a Military Student Pilot. 38
30219121 2018
34
Superior Canal Dehiscence Involving the Superior Petrosal Sinus: A Novel Classification Scheme. 38
30199501 2018
35
Minimally invasive surgery for superior semicircular canal dehiscence: Results of a four fenestration technique in twenty-one adults. 38
29741293 2018
36
Audiometric and cVEMP Thresholds Show Little Correlation With Symptoms in Superior Semicircular Canal Dehiscence Syndrome. 38
30124614 2018
37
Reducing Radiation Dose for High-resolution Flat-panel CT Imaging of Superior Semicircular Canal Dehiscence. 38
30113564 2018
38
Novel Method of Measuring Canal Dehiscence and Evaluation of its Potential as a Predictor of Symptom Outcomes After Middle Fossa Craniotomy. 38
28945893 2018
39
Peripheral Vestibular Disorders in Children and Adolescents with Concussion. 38
29685082 2018
40
Incidence of intraoperative hearing loss during middle cranial fossa approach for repair of superior semicircular canal dehiscence. 38
29908720 2018
41
Aggregating the symptoms of superior semicircular canal dehiscence syndrome. 38
29280497 2018
42
Clinical Implications of the Association Between Temporal Bone Tegmen Defects and Superior Semicircular Canal Dehiscence. 38
29697584 2018
43
[Application of technique of HRCT and multipliate plane reconstruction in analysis of image features of superior semicircular canal dehiscence]. 38
30550152 2018
44
Round window plugging in the treatment of superior semicircular canal dehiscence. 38
28990655 2018
45
Bone Metabolic Markers in the Clinical Assessment of Patients with Superior Semicircular Canal Dehiscence. 38
29452318 2018
46
Middle cranial fossa approach for the repair of superior semicircular canal dehiscence is associated with greater symptom resolution compared to transmastoid approach. 38
29022108 2018
47
The influence of the subarcuate artery in the superior semicircular canal dehiscence and its frequency on stillbirths: illustrative cases and systematic review. 38
29272988 2018
48
Semicircular canal dehiscence among idiopathic intracranial hypertension patients. 38
28833207 2018
49
RESPONSE TO "MICHAEL YONG, ERICA ZAIA, BRIAN WESTERBERG, AND JANE LEA. DIAGNOSIS OF SUPERIOR SEMICIRCULAR CANAL DEHISCENCE IN THE PRESENCE OF CONCOMITANT OTOSCLEROSIS". OTOL NEUROTOL 2017;38: 1071-1075. 38
29494468 2018
50
The Efficacy of Magnetic Resonance Imaging for the Diagnosis of Superior Semicircular Canal Dehiscence. 38
29283100 2018

Variations for Superior Semicircular Canal Dehiscence

Expression for Superior Semicircular Canal Dehiscence

Search GEO for disease gene expression data for Superior Semicircular Canal Dehiscence.

Pathways for Superior Semicircular Canal Dehiscence

GO Terms for Superior Semicircular Canal Dehiscence

Sources for Superior Semicircular Canal Dehiscence

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....